Long-Term Oncological Outcomes in Women Undergoing Radical Cystectomy and Orthotopic Diversion for Bladder Cancer

Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089, USA.
The Journal of urology (Impact Factor: 4.47). 04/2009; 181(5):2052-8; discussion 2058-9. DOI: 10.1016/j.juro.2009.01.020
Source: PubMed


We compared oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder transitional cell carcinoma.
From 1990 to 2005, 201 women underwent radical cystectomy, including 120 with an orthotopic neobladder. Median followup was 8.6 years. The clinical course, and pathological and oncological outcomes in these 120 women were analyzed and compared to those in 81 women undergoing radical cystectomy and cutaneous diversion during the same period.
Overall 3 of 120 women (2.5%) who received a neobladder died perioperatively. In this group the tumor was pathologically organ confined in 73 patients (61%), extravesical in 18 (15%) and lymph node positive in 29 (24%). Overall 5 and 10-year recurrence-free survival was 62% and 55%, respectively. Five and 10-year recurrence-free survival in patients with organ confined and extravesical disease was similar at 75% and 67%, and 71% and 71%, respectively. Patients with lymph node positive disease had significantly worse 5 and 10-year recurrence-free survival (24% and 19%, respectively). One woman had recurrence in the urethra and 2 (1.7%) had local recurrence. As stratified by pathological subgroups, similar outcomes were observed when comparing women with an orthotopic neobladder to the 81 who underwent cutaneous diversion.
Orthotopic diversion does not compromise the oncological outcome in women after radical cystectomy for bladder transitional cell carcinoma. Excellent local and urethral control may be expected. Women with node positive disease are at highest risk for recurrence. Similar outcomes were observed in women undergoing cutaneous diversion.

15 Reads
  • Source
    • "Patients learn to void through simultaneous relaxation of the pelvic muscles with coordinated increase in their intra-abdominal pressure (Valsalva maneuver) [12, 16, 17]. Clean intermittent catheterization (CIC) is required to manage urinary retention or periodically for irrigation of excessive mucous [12, 16, 17]. Patients who are not able to catheterize themselves practice timed voiding (since normal bladder sensation and urge are no longer intact). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bladder cancer is the fifth most commonly diagnosed cancer and the most expensive adult cancer in average healthcare costs incurred per patient in the USA. However, little is known about factors influencing patients' treatment decisions, quality of life, and responses to treatment impairments. The main focus of this paper is to better understand the impact of muscle invasive bladder cancer on patient quality of life and its added implications for primary caregivers and healthcare providers. In this paper, we discuss treatment options, side effects, and challenges that patients and family caregivers face in different phases along the disease trajectory and further identify crucial areas of needed research.
    Advances in Urology 08/2012; 2012(1):142135. DOI:10.1155/2012/142135
  • Source
    • "The tumors consisted of 73 organ-confined (61%), 18 extravesical (15%), and 29 lymph node positive diseases. Even though lymph node positive diseases have significantly worst recurrence-free survival, only two patients had local recurrences (12). However, Dhar et al. reviewed 685 patients treated with RC, and analyzed 130 pelvic recurrences without concomitant distant metastasis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thus far, the role of adjuvant radiotherapy (RT) after radical cystectomy (RC) in urinary bladder cancer patients has yet to be defined. The purpose of this study is to analyze patterns of failure, and suggest the rationale for RT. Between 1986 and 2005, a total of 259 patients treated with RC and pelvic lymph node dissection was enrolled. The age range was 27-82 yr (median, 62 yr). Node positivity increased according to tumor staging. Patients were divided into the following two groups based on pathologic analysis: organ-confined disease group (n=135) and extravesical/lymph node-positive disease group (n=80). Pelvic failures (PF) were observed in 8 (4.9%) in organ-confined disease group, and 21 (21.7%) in extravesical/lymph node-positive disease group. Five-year PF-free survival rates were 91.2% in organ-confined disease group and 68.0% in extravesical/lymph node-positive disease group. Five-year cancer-specific survival rates were 86.2% in organ-confined disease group and 53.9% in extravesical/lymph node-positive disease group. In conclusion, a relatively high PF rate was observed in extravesical lymph node-negative and lymph node-positive disease patients in this study. Adjuvant pelvic RT may be considered to reduce pelvic failures in extravesical lymph node-positive bladder cancer. Future prospective trials are required to test the clinical benefit of adjuvant RT.
    Journal of Korean medical science 06/2010; 25(6):835-40. DOI:10.3346/jkms.2010.25.6.835 · 1.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund und Fragestellung Im Zuge der demographischen Entwicklung steigt die Inzidenz und damit der Anteil an älteren Patientinnen, die am Harnblasenkarzinom erkranken. Ziel dieser Studie war es, klinische, onkologische und funktionelle Langzeitergebnisse von älteren Patientinnen (≥ 70 Jahre) zu analysieren, die mittels Zystektomie und Ileumneoblase behandelt wurden. Studiendesign und Untersuchungsmethoden Von 1995–2010 wurden 121 Patientinnen mit klinisch organbegrenztem Harnblasenkarzinom an der Urologischen Universitätsklinik Ulm aufgrund eines Harnblasenkarzinoms mittels radikaler Zystektomie und Anlage einer Ileumneoblase behandelt und im Rahmen dieser Studie bzgl. ihrer funktionellen und onkologischen Ergebnisse evaluiert. Zwei Altersgruppen zum Zeitpunkt der Zystektomie wurden verglichen (≥ 70 Jahre, n = 24 vs. < 70 Jahre, n = 97). Alle innerhalb der ersten 90 Tage aufgetretenen Komplikationen wurden analysiert, definiert und entsprechend dem modifizierten Clavien-System klassifiziert. Ergebnisse Die Gesamtkomplikationsrate betrug für Patientinnen ≥ 70 bzw. < 70 Jahren 66,7% bzw. 62,5%, anteilig daran waren 54,2% bzw. 44,8% sog. Minorkomplikationen, 12,5% bzw. 17,7% Majorkomplikationen. Mit 36,7% waren die häufigsten Komplikationen infektbedingt. In der Univariatanalyse zeigten sich weder das Alter noch die Komorbidität als signifikante Vorhersageparameter für die Inzidenz von Komplikationen. Die Kontinenzraten (0–1 Vorlage) waren tagsüber in beiden Gruppen vergleichbar (71% bzw. 82%; p = 0,64), jüngere Frauen zeigten jedoch eine signifikant höhere nächtliche Kontinenzrate (43% vs. 89%; p = 0,013). Weder in der uni- noch in der multivariaten Analyse erwies sich das Alter als prognostischer Faktor für das tumorspezifische Überleben. Schlussfolgerung Das chronologische Alter per se scheint auch bei Frauen keine Kontraindikation für den orthotopen Harnblasenersatz darzustellen, auch wenn potentiell mit höheren Inkontinenzraten gerechnet werden sollte.
    Der Urologe 10/2012; 51(10). DOI:10.1007/s00120-012-3019-y · 0.44 Impact Factor
Show more

David F Penson